PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- MSD, Bayer Yakuhin to Comarket Zetia-Statin Combo Drugs
July 10, 2017
- Maruho Takes Over Marketing Authorization for Astellas’ Protopic Ointment
July 10, 2017
- RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
- Konica Minolta Buying US Diagnostics Firm to Fully Enter Precision Medicine Biz
July 7, 2017
- Nippon Chemiphar Sounds Positive about Authorized Generic Biz
July 7, 2017
- Shire Japan Files Hereditary Angioedema Drug Icatibant
July 7, 2017
- AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race
July 7, 2017
- Meiji Seika Pharma Launches 1st AG with Meiact Generic
July 6, 2017
- Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations
July 6, 2017
- Daiichi Sankyo Drops Enbrel Biosimilar Development in Japan
July 6, 2017
- Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen
July 5, 2017
- Sumitomo Dainippon’s US Subsidiary Renamed
July 5, 2017
- J-TEC Wins Cultured Epidermis Order from Nagoya City Univ. Hospital
July 4, 2017
- French Biotech Oncodesign Set to Expand POC Services
July 4, 2017
- Aspen Japan to Take Over 4 Brands from Kyowa Kirin
July 4, 2017
- Sanofi Succeeds 4 Boehringer Brands in Japan under Global Asset Swap
July 4, 2017
- Signifor Filed for Cushing’s Disease in Japan: Novartis
July 4, 2017
- FDA Accepts NDA Resubmission for Sunovion’s COPD Med
July 4, 2017
- Evaluate Forecasts CAGR of 3.3% for Japan Market
July 4, 2017
- Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs
July 4, 2017
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…